George Yaghmour, Associate Director of USC Norris Blood and Marrow Transplant Program at University of Southern California, shared on LinkedIn:
“Excited to share our recent findings on FLT3 inhibitor maintenance therapy post-HSCT, showing promising outcomes. Our study highlights the importance of timing and choice of inhibitors in improving patient survival.
The study, limited by its single-center focus and observational nature, leaves room for considerations such as clinician decisions, inhibitor choice, and donor factors affecting outcomes.”
Visit the article website.
Source: George Yaghmour/LinkedIn